Published in Cancer Weekly, June 2nd, 2009
"Patients received irinotecan, 180 mg/m(2) infused over 90 min on day 1, followed by oxaliplatin, 85 mg/m(2) in a 3-hr infusion on day 2, and capecitabine, 1000 mg/m(2)/day orally twice daily from days 2 to 6 of a biweekly schedule. Treatment was continued Lip to 8 cycles or until progression of disease occurred. Response (RECIST criteria) was assessed after the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly